THE CANNABINOID INDEX
Cannabis produces many cannabinoids beyond the handful that appear in meaningful quantity, and reviews do not agree on the exact number, so we hold a figure until it can be cited. What follows is grouped by where each compound sits in the plant, from the major cannabinoids through the acidic precursors to the rare homologues. Each entry is chemistry and mechanism, with sources. Clinical evidence is held for registered practitioners, where it belongs.
See how well we know each figureMAJOR
Greater than one percent of plant composition
- Chemistry
- Formula C21H30O2. Molecular weight 314.46 g/mol. CAS 1972-08-3. Boiling point 157C at 0.02 mmHg, a vacuum distillation figure that does not describe behavior at atmospheric pressure. Typically 10 to 30 percent in high-THC cultivars.
- Receptor behavior
- CB1 partial agonist, Ki 10 to 40 nM. CB2 weak agonist. The CB1 figure is corroborated at 40 nM in an independent binding assay.
- Mechanism
- At CB1 in the central nervous system it reduces release of neurotransmitters including GABA, glutamate, dopamine, and norepinephrine. It modulates adenylyl cyclase, lowering cyclic AMP, and acts on calcium and potassium channels to reduce neuronal excitability. Its behavior is partial rather than full agonism: it occupies the receptor without producing the maximal response a full agonist would.
- In extraction
- Highly lipophilic; extracts efficiently in hydrocarbon, ethanol, and supercritical CO2. Decarboxylates from THCA beginning near 105C, optimal at 115 to 120C. Oxidizes to CBN under oxygen, light, and heat, so cold and dark storage is a preservation requirement rather than a preference. Crystallizes at room temperature with a melting point of 28 to 31C.
- In our process
- Ice water separation never approaches the decarboxylation threshold, so the material entering the press is predominantly THCA. Conversion happens under the platens, which is why press temperature is the single variable that sets the neutral cannabinoid content of a finished rosin.
- Evidence
- UNKNOWN
- Sources
- 1Citti C, et al. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than tetrahydrocannabinol: Tetrahydrocannabiphorol. Scientific Reports, 9, 20335.
- Chemistry
- Formula C21H30O2. Molecular weight 314.46 g/mol. CAS 13956-29-1. Boiling point 180C at 0.02 mmHg, a vacuum distillation figure. Ranges widely from 0.5 to 20 percent by chemotype.
- Receptor behavior
- CB1 negative allosteric modulator. CB2 weak partial agonist. 5-HT1A agonist. TRPV1 agonist. GPR55 antagonist.
- Mechanism
- CBD shares a molecular formula with THC and almost none of its receptor behavior. Rather than activating CB1 it binds a separate site and lowers the receptor responsiveness to compounds that do, which is why it attenuates the activity of THC. Its other activity happens largely outside the cannabinoid receptors, at 5-HT1A, TRPV1, GPR55, and PPAR, which is why its pharmacology is described as promiscuous rather than targeted.
- In extraction
- Crystallizes readily to an isolate above 99 percent purity. More stable than THC and less prone to oxidation. Decarboxylates from CBDA at 120 to 140C, more slowly than THCA. Poorly water soluble, so beverages and emulsions require additional processing.
- In our process
- THCA and CBDA do not decarboxylate at the same rate. A press schedule tuned for one is not tuned for the other, and material carrying both will convert unevenly under a single temperature hold.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
MINOR
One tenth to one percent of plant composition
- Chemistry
- Formula C21H32O2. Molecular weight 316.48 g/mol. CAS UNKNOWN. Boiling point UNKNOWN. Typically 0.5 to 2 percent in most cultivars, up to 15 percent in CBG-dominant selections.
- Receptor behavior
- CB1 weak partial agonist. CB2 moderate affinity. Alpha-2 adrenoceptor agonist. TRPV1 agonist. 5-HT1A antagonist.
- Mechanism
- CBG occupies an unusual position: its acidic form is the substrate that plant enzymes convert into the acidic precursors of THC, CBD, and CBC. What remains as CBG in a finished plant is largely what was not converted. Its receptor activity is spread across cannabinoid and non-cannabinoid targets, with notably more adrenergic involvement than the other major compounds.
- In extraction
- UNKNOWN
- Worth noting
- Because CBGA is consumed during biosynthesis, a high-CBG cultivar is one selected to arrest that conversion rather than one that produces more of it.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C21H30O2. Molecular weight 314.46 g/mol. CAS UNKNOWN. Boiling point UNKNOWN. Typically 0.1 to 1 percent, higher in some landrace populations.
- Receptor behavior
- CB1 very weak. CB2 moderate agonist. TRPV1 agonist. TRPA1 agonist.
- Mechanism
- CBC is the third product of the CBGA branch point, formed by its own synthase enzyme alongside those producing THCA and CBDA. Its activity sits largely outside the cannabinoid receptors, at the transient receptor potential channels TRPV1 and TRPA1 that also respond to capsaicin and to mustard oil compounds.
- In extraction
- Degrades to CBL under acidic conditions. Converts to CBT with heat and ultraviolet exposure. Decarboxylation behavior of CBCA UNKNOWN.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C21H26O2. Molecular weight 310.43 g/mol. CAS UNKNOWN. Boiling point UNKNOWN. Typically 0.1 to 2 percent, rising with storage time.
- Receptor behavior
- CB1 partial agonist, Ki 211 nM. CB2 partial agonist, Ki 96 nM. Roughly one tenth the potency of THC.
- Mechanism
- CBN is not primarily a biosynthetic product. It forms when THC oxidizes, so its concentration in a sample is largely a record of that sample history rather than of its genetics. It binds both cannabinoid receptors with lower affinity than THC and, unusually among the cannabinoids, binds CB2 more readily than CB1.
- In extraction
- CBN content is a storage artifact. Rising CBN in a stored product indicates oxidative degradation of THC and is a stability indicator rather than a feature.
- On the evidence
- CBN is widely marketed as a sleep compound. The evidence for that activity is limited, and the study most often cited for it came from a commercial laboratory and was not peer reviewed. CedarGrowth does not make that claim.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C19H26O2. Molecular weight 286.41 g/mol. CAS UNKNOWN. Boiling point UNKNOWN. A propyl analog with a three-carbon side chain against the five-carbon chain of THC. Typically 0.1 to 2 percent, up to 8 to 15 percent in certain African landrace populations.
- Receptor behavior
- CB1 antagonist at low concentration, agonist at high. CB2 partial agonist. CB1 Ki 75.4 nM in a comparative binding assay.
- Mechanism
- THCV differs from THC by two carbons on the side chain, and that difference reverses its behavior at CB1 across a concentration range: at low levels it blocks the receptor, at higher levels it activates it. It is the clearest illustration in the plant of why side chain length is treated as the pharmacophore in this compound class.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- 1Citti C, et al. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than tetrahydrocannabinol: Tetrahydrocannabiphorol. Scientific Reports, 9, 20335.
- Chemistry
- Formula C19H26O2. Molecular weight 286.41 g/mol. CAS UNKNOWN. Boiling point UNKNOWN. A propyl analog of CBD. Typically 0.1 to 1 percent, up to 10 percent in selected cultivars.
- Receptor behavior
- TRPV1 agonist. TRPV2 agonist. TRPM8 antagonist. Cannabinoid receptor behavior UNKNOWN.
- Mechanism
- CBDV stands in the same relationship to CBD that THCV stands to THC: two fewer carbons on the side chain. Its documented activity is at the transient receptor potential channels rather than at the cannabinoid receptors, consistent with the weak cannabinoid receptor binding of CBD itself.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C19H26O2, derived by homology from CBC. Molecular weight 286.41 g/mol, derived. CAS UNKNOWN. Boiling point UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBCV is the three-carbon side chain form of CBC, produced by the same synthase acting on the propyl precursor rather than the pentyl one. Its receptor behavior has not been characterized in material available here.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C19H28O2, derived by homology from CBG. Molecular weight 288.43 g/mol, derived. CAS UNKNOWN. Boiling point UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBGV is the propyl form of the precursor compound. Where CBGA feeds the pentyl series, its varin counterpart feeds the propyl one, which is why cultivars rich in THCV and CBDV are also where CBGV appears.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
ACIDIC PRECURSORS
Raw plant forms, before heat
These are the forms the plant actually makes. Every neutral cannabinoid on this page exists in living material as its acid, carrying an additional carboxyl group, and becomes neutral only when heat drives that group off as carbon dioxide. Nothing pressed cold is fully decarboxylated, and nothing decarboxylated is unchanged.
- Chemistry
- Formula C22H32O4, derived as CBG plus CO2. Molecular weight 360.49 g/mol, derived. CAS UNKNOWN. Decarboxylation threshold UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBGA is formed from a terpene precursor and a phenolic acid, then acted on by one of three synthase enzymes to produce THCA, CBDA, or CBCA. Which enzyme a plant expresses is what determines its chemotype. CBGA remaining in finished material is the portion never converted.
- In extraction
- Decarboxylates to CBG with heat, threshold UNKNOWN.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C22H30O4. Molecular weight 358.47 g/mol. CAS UNKNOWN. Decarboxylation 104 to 110C. Typically 10 to 30 percent in high-THC raw material.
- Receptor behavior
- PPAR gamma agonist. Cannabinoid receptor binding UNKNOWN, and it does not produce intoxication, which distinguishes it sharply from its neutral form.
- Mechanism
- THCA carries a carboxyl group that THC does not, and that single structural difference is why raw cannabis is not intoxicating. The group is lost as carbon dioxide under heat. Its own documented activity is at the nuclear receptor PPAR gamma rather than at CB1.
- In extraction
- This is the compound that actually enters the press. Conversion begins at 104 to 110C, so every press schedule is implicitly a decarboxylation schedule, whether or not it is designed as one.
- In our process
- A cold press retains more THCA; a hot press converts more of it. Both are legitimate products and they are not the same product.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C22H30O4. Molecular weight 358.47 g/mol. CAS UNKNOWN. Decarboxylation above 120C, kinetics characterized. Typically 2 to 20 percent in high-CBD raw material.
- Receptor behavior
- COX-2 inhibitor. 5-HT1A agonist.
- Mechanism
- CBDA is CBD carrying a carboxyl group. Unlike the neutral form, its documented activity includes direct enzyme inhibition rather than receptor binding alone.
- In extraction
- Decarboxylates more slowly than THCA and at a higher threshold, 120 to 140C against 104 to 110C. Its kinetics have been measured directly, which makes this the one decarboxylation figure on the page citable to a primary source rather than asserted. Poor bioavailability in its own right.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C22H30O4, derived as CBC plus CO2. Molecular weight 358.47 g/mol, derived. CAS UNKNOWN. Decarboxylation threshold UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBCA is the third product of the CBGA branch point, formed by CBCA synthase. It decarboxylates to CBC.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula C20H26O4, derived as CBDV plus CO2. Molecular weight 330.42 g/mol, derived. CAS UNKNOWN. Decarboxylation threshold UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- UNKNOWN
- Mechanism
- The acid form of the propyl CBD analog, produced in cultivars expressing the propyl biosynthetic route.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
RARE AND EMERGING
Less than one tenth of one percent of plant composition
- Chemistry
- Formula C23H34O2, verified. Molecular weight 342.53 g/mol, derived from the verified formula. CAS UNKNOWN. Measured near 29 micrograms per gram in the Italian FM2 medicinal variety, against 39 milligrams per gram of THC in the same material.
- Receptor behavior
- CB1 Ki 1.2 nM. CB2 Ki 6.2 nM. Comparators from the same assay: THC 40 nM, THCB 15 nM, THCV 75.4 nM at CB1.
- Mechanism
- THCP differs from THC by two carbons on the alkyl side chain. Structural work indicates the longer chain reaches further into a hydrophobic channel in the CB1 binding pocket, occupying it along its full length where the shorter chain of THC reaches only part way. That fuller occupancy accounts for the affinity difference.
- In extraction
- Present at microgram-per-gram levels, below the reporting threshold of most standard cannabinoid panels, so it will not appear on a routine certificate of analysis.
- On the evidence
- Binding affinity is not potency and it is not effect. The figure describes how readily the molecule occupies the receptor in one assay. In the animal work from the same study THCP was active at 5 mg per kilogram against a 10 mg per kilogram minimum for THC, a more modest ratio and the more honest comparison. There is no human data. The evidence base is one in vitro binding assay and one mouse study with five animals per dose group.
- Evidence
- UNKNOWN
- Sources
- 1Citti C, et al. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than tetrahydrocannabinol: Tetrahydrocannabiphorol. Scientific Reports, 9, 20335.
- Chemistry
- Formula C23H34O2, verified. Molecular weight 342.53 g/mol, derived from the verified formula. CAS UNKNOWN. Measured near 243 micrograms per gram in the FM2 variety.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBDP was isolated alongside THCP in the same work, structurally characterized, and confirmed against a stereoselective synthesis. Its receptor interactions were not determined.
- In extraction
- UNKNOWN
- On the evidence
- A compound whose pharmacology has not been characterized is a compound whose pharmacology has not been characterized. The authors state that they did not treat evaluating its cannabimimetic activity as a priority, given how weakly CBD itself binds the cannabinoid receptors.
- Evidence
- UNKNOWN
- Sources
- 1Citti C, et al. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than tetrahydrocannabinol: Tetrahydrocannabiphorol. Scientific Reports, 9, 20335.
- Chemistry
- Formula C20H28O2, derived by homology from THC. Molecular weight 300.44 g/mol, derived. CAS UNKNOWN. Boiling point UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- CB1 Ki 15 nM.
- Mechanism
- THCB sits between THCV and THC in the homologous series, one carbon shorter than THC. Its binding affinity falls between them accordingly, the pattern the side chain structure-activity work predicts.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- 1Citti C, et al. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than tetrahydrocannabinol: Tetrahydrocannabiphorol. Scientific Reports, 9, 20335.
- Chemistry
- Formula C20H28O2, derived by homology from CBD. Molecular weight 300.44 g/mol, derived. CAS UNKNOWN. Boiling point UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBDB was identified in hemp-derived CBD material and characterized alongside its THC counterpart. The origin of the butyl series is not fully settled; one proposal is microbial modification of the corresponding pentyl compounds rather than direct biosynthesis.
- In extraction
- UNKNOWN
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula UNKNOWN. Molecular weight UNKNOWN. CAS UNKNOWN. Typical plant content UNKNOWN.
- Receptor behavior
- CB2 partial agonist.
- Mechanism
- CBE is a metabolite of CBD rather than a primary plant product. Its presence in a sample points to metabolic or degradative history.
- In extraction
- Appears in aged material.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula UNKNOWN. Molecular weight UNKNOWN. CAS UNKNOWN. Rare in fresh plant material.
- Receptor behavior
- UNKNOWN
- Mechanism
- CBL forms from CBC under acidic conditions. Like CBN, it is a compound whose presence records what has happened to a sample rather than what the plant produced.
- In extraction
- Formation is a degradation pathway, so rising CBL indicates the material has aged or been exposed.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING
- Chemistry
- Formula UNKNOWN. Molecular weight UNKNOWN. CAS UNKNOWN. Present at well under 0.1 percent, more abundant in some aged or UV-exposed samples.
- Receptor behavior
- UNKNOWN
- Mechanism
- Cannabicitran forms from CBC under heat and ultraviolet light. The abbreviation CBT is also used in much of the literature for cannabitriol, a different molecule; cannabicitran is sometimes written CBT-C to disambiguate. Interactions at CB1 and CB2 are not yet clear.
- In extraction
- Accumulates in aged or UV-exposed samples.
- Evidence
- UNKNOWN
- Sources
- CITATION PENDING